Uretron D/s Tablet
NDC 12539-144
Product Information
Uretron D/s (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate) is a UNAPPROVED DRUG OTHER-approved product labeled by Doral Pharmamedics Inc Dba A.g. Marin Pharmaceuticals. This medication is typically used as a increased large intestinal motility [pe]. It is supplied as a blue tablet for oral administration. This product entry covers the primary NDC 12539-144 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
SAT;902
Code Structure Chart
Product Details
What is NDC 12539-144?
What are the uses of this product?
What are Active Ingredients of this product?
- HYOSCYAMINE SULFATE .12 mg/1
- METHENAMINE 81.6 mg/1 - An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173)
- METHYLENE BLUE 10.8 mg/1 - A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.
- PHENYL SALICYLATE 36.2 mg/1
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 40.8 mg/1
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)
- SODIUM CATION (UNII: LYR4M0NH37) (Active Moiety)
- PHENYL SALICYLATE (UNII: 28A37T47QO)
- PHENYL SALICYLATE (UNII: 28A37T47QO) (Active Moiety)
- HYOSCYAMINE SULFATE (UNII: F2R8V82B84)
- HYOSCYAMINE (UNII: PX44XO846X) (Active Moiety)
- METHYLENE BLUE (UNII: T42P99266K)
- METHYLENE BLUE CATION (UNII: ZMZ79891ZH) (Active Moiety)
- METHENAMINE (UNII: J50OIX95QV)
- METHENAMINE (UNII: J50OIX95QV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)
- CROSPOVIDONE (UNII: 68401960MK)
- ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A)
- POLYVINYL ALCOHOL (UNII: 532B59J990)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1047786 - hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet
- RxCUI: 1087457 - Uretron D-S 0.12 MG / 81.6 MG / 10.8 MG / 36.2 MG / 40.8 MG Oral Tablet
- RxCUI: 1087457 - hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Uretron DS]
- RxCUI: 1087457 - Uretron D-S (hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG) Oral Tablet
Which are the Pharmacologic Classes of this product?
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Oxidation-Reduction Activity - [MoA] (Mechanism of Action)
- Oxidation-Reduction Agent - [EPC] (Established Pharmacologic Class)
* Please review the full disclaimer at the bottom of this page.